FzM1 is a negative allosteric modulator (NAM) of the Frizzled receptor FZD4. FzM1 reduces WNT5A-dependent WNT response element (WRE) activity (log EC50inh=-6.2). FzM1 binds to the allosteric binding site located on FZD4 intracellular loop 3 (ICL3) and changes the conformation of the receptor, ultimately inhibiting the WNT/β-catenin cascade.

Physicochemical Properties

Molecular Formula	C21H16N2O2S
Molecular Weight	360.43
Exact Mass	360.093
CAS #	1680196-54-6
PubChem CID	90478321
Appearance	White to light brown solid powder
Density	1.4±0.1 g/cm3
Boiling Point	518.3±50.0 °C at 760 mmHg
Flash Point	267.2±30.1 °C
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.779
LogP	5.29
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	3
Heavy Atom Count	26
Complexity	489
Defined Atom Stereocenter Count	0
InChi Key	OBTSACXGWYGCPK-UHFFFAOYSA-N
InChi Code	InChI=1S/C21H16N2O2S/c24-19-12-16(20-6-3-9-26-20)11-18(13-19)23-21(25)22-17-8-7-14-4-1-2-5-15(14)10-17/h1-13,24H,(H2,22,23,25)
Chemical Name	1-(3-hydroxy-5-thiophen-2-ylphenyl)-3-naphthalen-2-ylurea
Synonyms	FzM 1 FzM-1 FzM1
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

A Negative Allosteric Modulator of WNT Receptor Frizzled 4 Switches into an Allosteric Agonist. Biochemistry. 2018 Feb 6;57(5):839-851.

Solubility Data

Solubility (In Vitro)

DMSO : ~62.5 mg/mL (~173.40 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 2.08 mg/mL (5.77 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.77 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.7745 mL	13.8723 mL	27.7446 mL
	5 mM	0.5549 mL	2.7745 mL	5.5489 mL
	10 mM	0.2774 mL	1.3872 mL	2.7745 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.